Introduction {#s1}
============

Cancer is the second major cause of morbidity and mortality worldwide behind cardiovascular diseases, with an estimated over 8.7 million deaths in 2015 ([@B1]). Moreover, the number of incident cases has been rising dramatically and patients tend to be younger ([@B2], [@B3]). Although a large number of cancers could currently be diagnosed at an early stage, survival rates have not improved largely. Surgery remains the mainstay of treatment in clinically localized disease for solid tumors, but despite this option, 20--30% of those with localized disease could experience progression or recurrence postoperatively, and the most of those patients would die of the disease progression ([@B4]). However, no definite therapies have been identified to reduce the risk of recurrence, progression or death from cancer after surgical intervention. Over the past few years, tremendous advancements in personalized medicine and novel treatment options like targeted therapy and immunotherapy have raised hope of greatly prolonging cancer patient survival ([@B2], [@B5]).

Bisphosphonates are commonly-prescribed medications widely prescribed for the prevention and treatment of osteoporosis. They are generally well-tolerated with the most common side effects being renal toxicity, gastrointestinal reactions, osteonecrosis of the jaw, atypical fractures, atrial fibrillation, musculoskeletal complaints, and esophageal cancer ([@B6]--[@B8]). Currently, bisphosphonates have gained popularity within the oncology prevention and treatment fields, based on studies indicating reduced cancer risk and patient survival ([@B9]--[@B11]). Findings from epidemiological studies have prompted clinical trials evaluating bisphosphonates combined with other medications or as a single agent in the neoadjuvant and adjuvant setting in patients with solid cancer ([@B12]). Though the antineoplastic effects of bisphosphonates are still unclear, preclinical studies have demonstrated that they can affect tumor cell proliferation, growth-factor release, cancer-cell adhesion, invasion, and angiogenesis which might be enhanced through co-administration with chemotherapy agents, biological agents, or both ([@B13]--[@B15]). Moreover, bisphosphonates are also reported to affect tumor microenvironment degradation proteins and induce apoptosis ([@B16], [@B17]). They have also been indicated to exert antitumor effects of modulating cancer progression and metastasis through the mevalonate pathway ([@B18]).

Several observational studies have found potential associations between bisphosphonate exposure and cancer risk/survival including gastrointestinal cancer, colorectal cancer, endometrial and ovarian cancer, and these studies reported inconsistent findings ([@B11], [@B19]--[@B21]). Thus, we aimed to conduct a meta-analysis to examine whether use of bisphosphonates was associated with differential survival outcomes in patients diagnosed with solid cancer.

Materials and methods {#s2}
=====================

Search strategy
---------------

This meta-analysis was performed in accordance with the PRISMA guidelines ([@B22]) (Table [S4](#SM4){ref-type="supplementary-material"}). We conducted a computer-assisted search with the databases including PubMed, Cochrane Library, and Embase to identify relevant published studies on the prognostic effect of bisphosphonate use on the survival of solid cancers. We searched the databases from inception through March, 2018 with the following keywords: "diphosphonates or bisphosphonates" and "neoplasm^\*^ or cancer or tumor or tumor or carcinoma or malignanc^\*^" and "survival or mortality or death or prognos^\*^ or outcome" (Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}). Manual searches of reference lists from eligible studies were performed to identify potential missed studies during the computer-assisted search. We also conducted additional manual searches of some major journals on clinical oncology, such as "Lancet Oncology," "Journal of Clinical Oncology," "Annals of Oncology" and "Journal of The National Cancer Institute," and abstract from the American Society of Clinical Oncology (ASCO) meeting. Moreover, we also consulted expert oncologists to identify additional references or unpublished literature.

Study selection and inclusion criteria
--------------------------------------

Two authors (DW and ZX) reviewed all titles or abstracts of citations identified by the database search to retrieve potentially relevant articles. The full-text for each potentially relevant article was then reviewed by each of the two authors. The articles were cross checked by two independent authors for possible inclusion and disagreements were resolved through discussion or by consensus with a senior author (XW or JX).

Observational studies were satisfied the inclusion criteria and thus included for analysis if they (i) included patients clinically or pathologically diagnosed with solid cancer, (ii) evaluated and clearly defined exposure to any bisphosphonates, (iii) reported survival outcomes in patients with solid cancer, and (iv) reported hazard ratios (HRs) or relative risks (RRs) and their corresponding 95% CIs or provided relevant data for their calculation. If several publications shared the same cohort, we used the article with the most informative one.

Data abstraction
----------------

Two authors (DW and ZX) independently conducted data abstraction using a standardized form. The following data were summarized from each study: first author, publication year, tumor type, study design, study country, sex, sample size, follow-up duration, HR and 95% confidence intervals (CIs) with fully adjustment for confounding variables. Conflicts were resolved by discussion or by a senior author. One author (XW) assessed the quality of each study by Ottawa--Newcastle scale (NOS). After the resolution of discrepancies, a final NOS score for observational studies was obtained based on selection of involved population, comparability of study groups, and adequacy of outcome assessment ([@B23]).

Outcomes assessed
-----------------

The primary outcome measure was OS which defined as the time from the enrollment to death from any cause. The secondary outcome measures included CSS, defined as the time from the enrollment to death from a specific cancer type, and RFS, defined as the time from the enrollment to the first recorded disease recurrence or death from any cause, which would occurred first.

Statistical analysis
--------------------

Stata® version 12.0 (Stata Corp LP, College Station, Texas, USA) was applied to perform all statistical analyses. We used the DerSimonian and Laird random-effects model to calculate summarized HR and 95% CI ([@B24]). Summary estimates reported in studies adjusted for most confounding variables were used for analysis. Inter-study heterogeneity was tested by using Cochrane\'s *Q* test, defined as statistically significant if *p*-value was \< 0.10 or I^2^ statistic if an I^2^ statistic more than 50% representing significant heterogeneity ([@B25]). Random-effects models were used to meta-analyze each of the primary and secondary outcome measure. Subgroup analyses were also applied to examine the potential sources of heterogeneity, such as cancer type. Publication bias was assessed by visual inspection funnel plot asymmetry along with Begg\'s rank correlation test and Egger\'s linear regression test, with a *P*-value \< 0.1 as an indication of publication bias ([@B26], [@B27]).

Sensitivity analyses were performed to further investigate the sources of inter-study heterogeneity in terms of some major study characteristics for OS and CSS subset, which was also used to examine the robustness of the findings. The influence of individual study on the pooled estimates was conducted by omitting one study at a time and recalculating the others. Furthermore, subgroup differences were conducted using meta-regression analysis when necessary. A *P*-value of \< 0.05 was considered statistically significant.

Results {#s3}
=======

Literature search
-----------------

The database search yielded a total of 9,742 unique citations published through March, 2018. After title or abstract review, 43 records were potentially appropriate, which were further reviewed through full-text reading, and an additional 35 studies were excluded due to various reasons. Finally, eight studies with a total of 241,634 individuals met the inclusion criteria (Figure [1](#F1){ref-type="fig"}) for inclusion in the meta-analysis ([@B19], [@B28]--[@B34]).

![Flow chart for the process of identifying studies included in and excluded from the systematic review.](fonc-08-00495-g0001){#F1}

Study characteristics
---------------------

The characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. These studies were published from 2012 to 2018. Six of these studies were cohort studies ([@B19], [@B28]--[@B30], [@B33], [@B34]), and the remaining two were nested case-control studies ([@B31], [@B32]). Three studies were each from Europe and USA/Canada, respectively, and two studies represented the Asian population. Four studies investigated survival benefits of bisphosphonates in breast cancer patients ([@B28]--[@B31]), three in colorectal cancer patients ([@B19], [@B32], [@B33]) and one in gastroesophageal cancer patients ([@B34]). The median sample size of the included studies was 10,786 (range 1,706--153,030). The quality of the included studies was generally high with five of eight stars and three of nine stars.

###### 

Major baseline features of the included studies.

  **References**                            **Study design**                                         **Tumor location**                   **Study setting**   **Country**    **Sex**       **Exposure ascertment**                                      **Sample size**   **Follow-up**       **NOS**
  ----------------------------------------- -------------------------------------------------------- ------------------------------------ ------------------- -------------- ------------- ------------------------------------------------------------ ----------------- ------------------- ---------
  Korde et al. ([@B28])                     Population-based cohort study                            Early stage invasive breast cancer   Multiple center     USA            Female        Medical record, interview, and cancer registry data          1,813             Median 11.8 years   8
  Kwan et al. ([@B29])                      Hospital-based cohort study                              Breast cancer                        Multiple center     USA            Female        Electronic health records and cancer registries              16,781            Median 6.4 years    8
  Hicks et al. ([@B19])                     Prospective population-based cohort study                Colorectal cancer                    Multiple center     UK             Male/female   The UK Clinical Practice Research Datalink (CPRD)            4,791             Mean 3.3 years      9
  Kremer et al. ([@B30])                    Community-based cohort study                             Breast cancer                        Multiple center     Canada         Female        Prescription recorded database                               21,664            Median 5 years      9
  Rennert et al. ([@B31])                   Population-based nested case-control study               Breast cancer                        Multiple center     Israel         Female        Computerized prescription records                            3,731             Mean 5.83 years     8
  Rennert et al. ([@B32]) (Breast cohort)   Population-based nested case-control study               Breast cancer                        Multiple center     Israel         Female        Pharmacy records                                             1,706             Mean 5.8 years      8
  Pazianas et al. ([@B33]) (Colon cohort)   Population-based national register-based cohort study,   Colon cancer                         Multiple center     Denmark        Male/female   Medical record                                               38,118            Mean 4.9 years      8
  Abrahamsen et al. ([@B34])                Population-based national register-based cohort study,   Esophageal and Gastric Cancer        Multiple center     USA, Danmark   Male/female   Record of all hospitalizations and outpatient appointments   153,030           Mean 3.5 years      9

*CI, confidence interval; het, heterogeneity; HR, hazard ratio*.

Relationship between bisphosphonate use and solid cancer survival
-----------------------------------------------------------------

Five studies were involved in the analysis of bisphosphonate use and OS. Figure [2](#F2){ref-type="fig"} showed that bisphosphonate use was associated with prolonged OS (HR 0.84, 95% CI 0.76--0.93). We noted that there was evidence of heterogeneity (I^2^ = 81.4%).

![Summary estimates and 95% CIs for overall survival, cancer-specific survival and recurrence-free survival for associations between bisphosphonate use and survival of patients with solid tumors. Weights are from random effects analysis. CI, confidence interval; HR, hazard ratio; W (random), Weights (random effects model).](fonc-08-00495-g0002){#F2}

Six studies were involved in the analysis of bisphosphonate use and CSS. The result showed that bisphosphonate use was associated with prolonged CSS (HR 0.73, 95% CI 0.58--0.90). We noted that there was evidence of heterogeneity (I^2^ = 80.9%).

Three studies were involved in the analysis of bisphosphonate use and RFS. The result showed that bisphosphonate use was associated with prolonged RFS (HR 0.72, 95% CI 0.53--0.96). We noted that there was evidence of heterogeneity (I^2^ = 75.1%; Table [2](#T2){ref-type="table"}).

###### 

Meta-analysis of associations between bisphosphonate use and survival of patients with solid tumors.

  **Variable**                   **No of studies**   **HR (95% CI)**     ***P*-value**   **I^2^, *P*~het~**
  ------------------------------ ------------------- ------------------- --------------- --------------------
  Overall survival               5                   0.84 (0.76--0.93)   \< 0.001        81.5, \< 0.001
  Cancer-specific survival       6                   0.73 (0.58--0.90)   \< 0.001        80.9, \< 0.001
  Recurrence-free survival       3                   0.72 (0.53--0.96)   \< 0.001        75.1, \< 0.001
  **TUMOR LOCATION**                                                                     
  **Overall survival**                                                                   
      Colorectal cancer          2                   0.74 (0.43--1.27)   0.02            81.4, \< 0.001
      Breast cancer              2                   0.81 (0.63--1.04)   \< 0.001        90.7, \< 0.001
      Gastroesophageal cancer    1                   0.62 (0.40--0.98)   \< 0.001        81.5, \< 0.001
  **Cancer-specific survival**                                                           
      Colorectal cancer          3                   0.71 (0.44--1.15)   0.005           80.9, \< 0.001
      Breast cancer              3                   0.73 (0.55--0.95)   0.002           79.4, \< 0.001

*CI, confidence interval; het, heterogeneity; HR, hazard ratio*.

The results of subgroup analyses for the associations between bisphosphonate use and OS or CSS were presented in Tables [3A](#T3){ref-type="table"}, [3B](#T4){ref-type="table"}. Generally, the findings of most of the subgroups were statistically significant, favoring that bisphosphonate use was significantly associated with improved survival for solid cancer patients, which was consistent with the main results. Furthermore, we noted that heterogeneity for the majority of the subgroups significantly reduced, indicating the sources of heterogeneity might originate from difference in geographical location, study quality, study sample size, study design, gender, tumor stage, source of exposure, statistical method (Table [3](#T3){ref-type="table"}).

###### 

Subgroup analyzes for the associations between bisphosphonate use and overall survival of patients with solid tumors.

  **Variables**                      **No. of study**   **HR (95%CI)**      **I^2^ (%)**   ***P*[^\*^](#TN1){ref-type="table-fn"}**   ***P*[^\*\*^](#TN2){ref-type="table-fn"}**
  ---------------------------------- ------------------ ------------------- -------------- ------------------------------------------ --------------------------------------------
  Geographical location                                                                    \< 0.001                                   
      Europe                         3                  0.79 (0.57--1.12)   48.1           0.146                                      
      America                        2                  0.72 (0.63--0.81)   0              0.553                                      
      Asia                           2                  0.75 (0.42--1.35)   84             0.012                                      
  Study quality                                                                            \< 0.001                                   
      Low risk                       3                  0.94 (0.88--1.01)   76.3           0.015                                      
      High risk                      4                  0.71 (0.63--0.80)   0              0.674                                      
  Number of cases                                                                                                                     
       \< 10,000                     2                  0.75 (0.42--1.35)   84             0.012                                      0.006
      ≥10,000                        5                  0.77 (0.63--0.94)   78.4           0.001                                      
  Type of cohort                                                                           0.011                                      
      Retrospective                  4                  0.71 (0.48--1.05)   72.1           0.013                                      
      Prospective                    3                  0.80 (0.65--0.99)   86.7           0.001                                      
  Gender                                                                                   0.41                                       
      Female                         6                  0.74 (0.59--0.92)   84.2           \< 0.001                                   
      Both gender                    1                  0.93 (0.89--0.97)   N/A            N/A                                        
  Tumor stage                                                                              \< 0.001                                   
      I--IV                          5                  0.92 (0.85--1.00)   68.6           0.013                                      
      I--III                         2                  0.72 (0.63--0.81)   0              0.553                                      
  Source of exposure                                                                       N/A                                        
      Prescription database          7                  0.84 (0.76--0.93)   81.4           \< 0.001                                   
      Medical records                0                  N/A                 N/A            N/A                                        
  Statistical analysis                                                                     0.07                                       
      Time-dependent                 5                  0.85 (0.77--0.94)   85.8           \< 0.001                                   
      Non time-dependent             2                  0.62 (0.40--0.98)   0              0.361                                      
  Adjustment for major confounders                                                         0.303                                      
      Yes (Age, stage and grade)     4                  0.76 (0.60--0.97)   89             \< 0.001                                   
      No (Age, stage and grade)      3                  0.79 (0.57--1.12)   48.1           0.146                                      

*CI, confidence interval; HR, hazard ratio; N/A, not available*;

*P-value for heterogeneity within each subgroup*;

*P-value for heterogeneity between subgroups in meta-regression analysis*.

###### 

Subgroup analyses for the associations between bisphosphonate use and cancer-specific survival of patients with solid tumors.

  **Variables**                      **No. of study**   **HR (95%CI)**      **I^2^ (%)**   ***P*[^\*^](#TN3){ref-type="table-fn"}**   ***P*[^\*\*^](#TN4){ref-type="table-fn"}**
  ---------------------------------- ------------------ ------------------- -------------- ------------------------------------------ --------------------------------------------
  Geographical location                                                                                                               \< 0.001
   Europe                            2                  0.82 (0.46--1.45)   88.4           0.003                                      
   America                           3                  0.65 (0.52--0.82)   25.3           0.262                                      
   Asia                              2                  0.70 (0.34--1.43)   76.0           0.041                                      
  Study quality                                                                                                                       0.255
   Low risk                          4                  0.64 (0.45--0.92)   87.5           \< 0.001                                   
   High risk                         3                  0.82 (0.60--1.11)   66.5           0.050                                      
  Number of cases                                                                                                                     \< 0.001
    \< 10,000                        4                  0.76 (0.54--1.07)   77.3           0.004                                      
   ≥10,000                           3                  0.66 (0.57--0.76)   0              0.558                                      
  Type of cohort                                                                                                                      \< 0.001
   Retrospective                     2                  0.70 (0.34--1.43)   76.0           0.041                                      
   Prospective                       5                  0.71 (0.56--0.89)   66.7           0.017                                      
  Gender                                                                                                                              0.037
   Female                            5                  0.69 (0.52--0.91)   78.2           0.001                                      
   Both gender                       2                  0.82 (0.46--1.45)   88.4           0.003                                      
  Tumor stage                                                                                                                         0.002
   I--IV                             4                  0.79 (0.59--1.06)   83.9           \< 0.001                                   
   I--III                            3                  0.65 (0.52--0.82)   25.3           0.262                                      
  Source of exposure                                                                                                                  0.009
   Prescription database             6                  0.77 (0.62--0.95)   79.7           \< 0.001                                   
   Medical records                   1                  0.48 (0.30--0.76)   N/A            N/A                                        
  Statistical analysis                                                                                                                N/A
   Time-dependent                    7                  0.73 (0.58--0.90)   80.9           \< 0.001                                   
   Non time-dependent                0                  N/A                 N/A            N/A                                        
  Adjustment for major confounders                                                                                                    0.001
   Yes (Age, stage and grade)        6                  0.75 (0.60--0.95)   75.0           0.001                                      
   No (Age, stage and grade)         1                  0.62 (0.50--0.76)   N/A            N/A                                        

*CI, confidence interval; HR, hazard ratio; N/A, not available*;

*P-value for heterogeneity within each subgroup*;

*P-value for heterogeneity between subgroups in meta-regression analysis*.

Bisphosphonate use and survival in different cancer types
---------------------------------------------------------

For individual cancer type, we found that bisphosphonate use was significantly associated with longer OS for patients with gastroesophageal cancer (HR 0.62, 95% CI 0.40--0.98), but not for patients with breast (HR 0.74, 95% CI 0.43--1.27) or colorectal cancer (HR 0.81, 95% CI 0.63--1.04; Figure [3](#F3){ref-type="fig"}). Besides, bisphosphonate use was significantly associated with longer CSS for patients with breast cancer (HR 0.73, 95% CI 0.55--0.95), but not for patients with colorectal cancer (HR 0.71, 95% CI 0.44--1.15; Figure [4](#F4){ref-type="fig"}).

![Summary estimates and 95% CIs for overall survival associations between bisphosphonate use and survival of patients with solid tumors according to tumor location. Weights are from random effects analysis. CI, confidence interval; HR, hazard ratio; W (random), Weights (random effects model).](fonc-08-00495-g0003){#F3}

![Summary estimates and 95% CIs for cancer-specific survival of associations between bisphosphonate use and survival of patients with solid tumors according to tumor location. Weights are from random effects analysis. CI, confidence interval; HR, hazard ratio; W (random), Weights (random effects model).](fonc-08-00495-g0004){#F4}

Publication bias and sensitivity analyses
-----------------------------------------

As there were limited number of studies (\< 10) included in each study outcome subset, we did not assess publication bias. Sensitivity analyses by omitting one study at a time and recalculating the summary HRs for the remaining studies yielded consistent results for each outcome of OS, CSS and RFS subset (Figures [S1](#SM5){ref-type="supplementary-material"}--[S3](#SM7){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this meta-analysis of eight studies investigating the prognostic effect of bisphosphonate use on the survival of patients with solid cancer, we found that bisphosphonate use was associated with improved survival for patients with solid cancer in terms of OS, CSS and RFS. However, we did not find improved OS or CSS in all type of solid cancers. We noted considerable inter-study heterogeneity that could be explained by study design, tumor stage or sample size.

This meta-analysis is the first one to provide evidence for substantial prognostic role of bisphosphonate use in patients with solid cancer. Although several previous studies showed no prognostic association of bisphosphonate use in solid cancers ([@B19], [@B29], [@B34]), there was limited statistical power due to the small sample sizes in single study. These inconsistent results of the included studies might attribute to several factors. Firstly, the included studies had various sample sizes and we know that studies with smaller sample size could result in inconsistent risk estimates of effect sizes, which was prone to publication bias. Secondly, different study designs were applied to the included studies; some studies which conducted in single center used a convenience sample, mainly with huge selection bias, while others used samples from population-based samples or multiple institutions or in epidemiologic study settings. Thirdly, the basic disease characteristics, such as disease stage, tumor location, adjuvant treatment, follow-up duration, bisphosphonate type, dose and duration vary among studies, which might cause potential heterogeneity in study findings. In this study, we thoroughly conducted subgroup analyses according to tumor location and other potential major study characteristics for outcomes of OS and CSS and the findings were generally consistent and we initially considered that inter-study heterogeneity could attribute to these characteristics. Moreover, we found that there was little inter-study heterogeneity in stage I-III patients for OS and CSS subsets, and also in large studies (sample size ≥ 10,000; Tables [3A](#T3){ref-type="table"}, [3B](#T4){ref-type="table"}). Due to limited studies, further large prospective studies should be conducted in these subsets in the future. Fourthly, some more important molecular pathological data including KRAS, BRAF, PIK3CA, HER-2, ER, PR, and PD-L1 status, microsatellite instability status, CpG island methylator phenotype, microRNA expression, and other influential prognostic factors, which had been identified to be associated with specific cancer patient survival ([@B35]--[@B42]), could not be analyzed separatedly due to unavailability of these data in the included studies. Fifthly, due to the nature of observational study, we could not conclude the casual relationship between bisphosphonate use and reduced cancer mortality. Finally, we did not include gray literature or other unpublished literature, having the potentials to lead to publication bias.

Despite the above limitations, the present study also has several strengths. Firstly, we developed a set of comprehensive database search strategy for search without language limits, which could reduce the risk of missing studies to a great deal. Secondly, this is the largest meta-analysis with more than 153,000 participants involved which provided the most powerful evidence regarding this subject ever to date. Thirdly, at least two authors independently did the literature search, study selection and study quality assessment and the results were cross-checked by a senior author, which guaranteed the objective assessment of the systematic review.

Studies have indicated that several major side effects or adverse events are closely related to bisphosphonate use. It seems that people with bisphosphonate use have a higher risk of developing acute-phase reactions (fever, myalgias, lymphopenia, etc.), hypocalcemia, iritis, renal toxicity and osteonecrosis of the jaw ([@B43]--[@B47]). Despite all these side-effects, the major clinical implications of this study lies in that bisphosphonate use is significantly associated with improved survival for patients with solid cancer. Osteoporosis is a common status in a substantial number of patients diagnosed with malignancy who take bisphosphonates and bisphosphonate exposure is strongly correlated with decreased mortality and improved progression, even after adjustment for some clinical variables. Future research should be focused on large prospective studies or individual patient data meta-analyses to minimize the confounders in specific malignancies; moreover, we also consider more in that current evidence lacks evidence regarding drug dose and duration response of bisphosphonate use.
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